Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vestis Corporation due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's growth and business strategy [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Vestis between May 2, 2024, and May 6, 2025, to discuss their legal rights [1]. - There is an August 8, 2025, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Vestis [2]. - The complaint alleges that Vestis and its executives concealed material adverse facts regarding the company's ability to grow its business and execute strategic initiatives [4]. Group 2: Financial Performance and Stock Impact - On May 7, 2025, Vestis announced disappointing financial results for Q2 of fiscal 2025, withdrawing its revenue and growth guidance for the full fiscal year [5]. - The company attributed its poor performance to "lost business in excess of new business" and "lower adds over stops," indicating a decline in customer volume [5]. - Following the announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [5].

Core Viewpoint - A shareholder class action lawsuit has been filed against Civitas Resources, Inc. alleging misleading statements and failure to disclose adverse information regarding its business and operations [1] Group 1: Allegations in the Lawsuit - The lawsuit claims that Civitas is likely to significantly reduce its oil production in 2025 due to declines following the production peak at the DJ Basin in Q4 2024 and a low turned-in-lines count at the end of 2024 [1] - It is alleged that increasing oil production would require Civitas to acquire additional acreage and development locations, leading to significant debt and potential asset sales to offset acquisition costs [1] - The financial condition of Civitas may necessitate disruptive cost-reduction measures, including a significant workforce reduction [1] - Consequently, the lawsuit asserts that Civitas's business and financial prospects, as well as its operational capabilities, were overstated [1]

Core Insights - Holzer & Holzer, LLC is investigating whether Altimmune, Inc. complied with federal securities laws following the announcement of topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) [1] - The trial results indicated that there was no statistical significance in improving fibrosis without worsening MASH, leading to a decline in Altimmune's stock price [1] Company Overview - Altimmune, Inc. is a publicly traded company on NASDAQ under the ticker symbol ALT [1] - The company is currently facing scrutiny regarding its compliance with federal securities laws due to the recent trial results [1] Legal Context - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in litigation, including class action and derivative litigation [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

Core Insights - Holzer & Holzer, LLC is investigating Ichor Holdings, Ltd. for potential compliance issues with federal securities laws following disappointing Q1 2025 financial results [1] - Ichor's CEO indicated that the company's strategy did not yield the expected margin flow due to higher-than-forecasted external supply purchases [1] - The announcement of these results led to a decline in Ichor's stock price [1] Company Overview - Ichor Holdings, Ltd. trades on NASDAQ under the ticker ICHR [1] - The company reported its Q1 2025 financial results on May 5, 2025 [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation, representing shareholders and investors in various legal actions [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

Core Insights - Holzer & Holzer, LLC is investigating Myriad Genetics for potential compliance issues with federal securities laws following a significant decline in pharmacogenomics revenue [1] - Myriad Genetics reported a 20% year-over-year decline in pharmacogenomics revenue attributed to UnitedHealthcare reducing coverage of GeneSight [1] - The company's stock price dropped after the announcement of its first quarter 2025 financial results and lowered financial guidance [1]

Core Viewpoint - A class action lawsuit has been filed against Compass Group Diversified Holdings LLC due to alleged failures in financial reporting and internal controls, leading to significant stock price decline following the revelation of these issues [3][4][5]. Group 1: Lawsuit Details - The class action lawsuit, Nicholas Moreno v. Compass Group Diversified Holdings LLC, has been amended and is ongoing in the United States District Court for the District of Connecticut [1]. - The lawsuit pertains to securities purchased between February 24, 2022, and May 7, 2025, and claims that Compass failed to disclose critical information regarding its subsidiary, Lugano Holding, Inc. [1][3]. Group 2: Financial Reporting Issues - Compass Group's internal controls over financial reporting were deemed ineffective, and undisclosed financing arrangements related to Lugano were highlighted as problematic [3]. - The company announced on May 7, 2025, that its financial statements for fiscal 2024 could no longer be relied upon due to an internal investigation into Lugano's financing of inventory [4]. Group 3: Stock Price Impact - Following the announcement of the investigation, Compass' stock price plummeted from $17.25 per share on May 7, 2025, to $6.55 per share on May 8, 2025, indicating a dramatic loss in market value [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Iovance Biotherapeutics, Inc. due to allegations of false and misleading statements regarding the company's growth potential and operational capabilities [2][4]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $100,000 in Iovance between August 8, 2024, and May 8, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Iovance, with a deadline of July 14, 2025, for investors to seek the role of lead plaintiff [2][6]. - The complaint alleges that Iovance and its executives violated federal securities laws by failing to disclose the true state of the company's growth potential and operational readiness [4]. Group 2: Financial Performance and Stock Impact - On July 25, 2024, Iovance announced a reduction in its revenue guidance for the full fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and a variable pace in treatment initiation [5]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in just one day [5].

Core Viewpoint - UroGen Pharma Ltd. is facing a federal securities class action due to allegations of misleading statements regarding the effectiveness of its drug UGN-102, leading to significant stock price declines following negative FDA feedback and advisory committee decisions [4][5][6]. Group 1: Legal Action and Investor Information - Faruqi & Faruqi, LLP is investigating potential claims against UroGen and reminds investors of the July 28, 2025 deadline to seek the role of lead plaintiff in the class action [2]. - Investors who suffered losses exceeding $75,000 in UroGen between July 27, 2023, and May 15, 2025, are encouraged to contact the firm for legal options [1]. - The court-appointed lead plaintiff will represent the interests of the class and any member can move to serve as lead plaintiff [7]. Group 2: Allegations Against UroGen - The complaint alleges that UroGen and its executives violated federal securities laws by making false statements and failing to disclose critical information about the ENVISION clinical study [4]. - Specific allegations include the study's lack of a concurrent control arm, which undermined the ability to demonstrate the drug's effectiveness, and the company's disregard for FDA warnings regarding study design [4]. - As a result of these issues, there was a substantial risk that the new drug application (NDA) for UGN-102 would not be approved, leading to misleading positive statements about the company's prospects [4]. Group 3: Stock Price Impact - Following the FDA's briefing document questioning the effectiveness of UGN-102, UroGen's stock price fell by $2.54, or 25.8%, closing at $7.31 per share on May 16, 2025 [5]. - After the Oncologic Drugs Advisory Committee voted against the NDA for UGN-102, the stock price dropped by $3.37, or 44.7%, closing at $4.17 per share on May 21, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly providing misleading information regarding the safety and clinical trial protocol of its RP-A501 treatment, leading to significant financial losses for investors [1][3]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Rocket securities between February 27, 2025, and May 26, 2025, with a deadline of August 11, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Rocket made positive statements while concealing serious risks, including the occurrence of Serious Adverse Events (SAEs) during clinical trials [3]. Clinical Trial Issues - Rocket amended the trial protocol to include a new immunomodulatory agent without informing shareholders, which is claimed to have misled investors about the safety of the treatment [3]. - On May 27, 2025, the FDA placed a clinical hold on the RP-A501 Phase 2 study after a patient suffered a SAE, which included death, following the undisclosed protocol amendment [4]. Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in one trading day [5].

Core Viewpoint - A securities class action lawsuit has been filed against PepGen Inc. for allegedly making false and misleading statements regarding its lead product candidate, PGN-EDO51, and its clinical trials [1][2]. Group 1: Lawsuit Details - The lawsuit covers all investors who purchased PepGen securities between March 7, 2024, and March 3, 2025 [1]. - Investors are encouraged to contact the law firm before the lead plaintiff motion deadline of August 8, 2025 [2]. Group 2: Allegations Against PepGen - The complaint alleges that PepGen misrepresented the efficacy and safety of PGN-EDO51, claiming it was less effective than publicly stated [8]. - The CONNECT2 study was described as dangerous or deficient for obtaining FDA approval, undermining the drug's clinical, regulatory, and commercial prospects [8]. - The truth about the drug's performance began to emerge on July 30, 2024, when PepGen reported "positive clinical data" that fell short of expectations, leading to a significant stock price drop of 32.69% [3][4].